Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA
Tóm tắt
The purpose of this study was to describe comorbidities, healthcare costs, and resource utilization among patients with chronic non-infectious uveitis initiating corticosteroid, immunosuppressants, or biologics. In this retrospective cohort study, patients with a non-infectious uveitis diagnosis and continuous insurance coverage during a 6-month baseline were selected from a privately insured claims database with 80.7 million enrollees. Index dates were defined as the first prescription/administration of a corticosteroid, immunosuppressant, or biologic between 2003 and 2009. Comorbidities, healthcare costs, and utilization were analyzed in a per-member-per-month (PMPM) framework to account for varying between-patient treatment periods, defined as continuous medication use within the same class. Wilcoxon rank-sum and chi-square tests were used for comparisons of costs and categorical outcomes. Patients on corticosteroids (N = 4,568), immunosuppressants (N = 5,466), and biologics (N = 1,694) formed the study population. Baseline PMPM inpatient admission rates were 0.029 for patients on corticosteroids, 0.044 for patients on immunosuppressants, and 0.045 for patients on biologics (p < 0.001 immunosuppressants or biologics versus corticosteroids); during treatment, PMPM inpatient admissions increased to 0.044 and 0.048 for patients taking corticosteroids and immunosuppressants, respectively, but decreased to 0.024 for patients taking biologics (p < 0.001 versus corticosteroids and p = 0.003 versus immunosuppressants). Baseline average PMPM costs for patients taking corticosteroids, immunosuppressants, and biologics were US$935, US$1,738, and US$1,439 (p < 0.001 between groups), while on-treatment PMPM costs excluding drug costs increased to US$1,129 for patients taking corticosteroids but lowered to US$1,592 for patients taking immunosuppressants, and US$918 for patients taking biologics (p < 0.001 versus corticosteroids or immunosuppressants). There is significant economic burden associated with existing treatments of uveitis. Corticosteroids may be overused as a treatment for uveitis.
Tài liệu tham khảo
Chang JH, Wakefield D: Uveitis: a global perspective. Ocul Immunol Inflamm 2002, 10: 263–279. 10.1076/ocii.10.4.263.15592
Suttorp-Schulten MS, Rothova A: The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 1996, 80: 844–848. doi:10.1136/bjo.80.9.844 10.1136/bjo.80.9.844
Darrell RW, Wagener HP, Kurland LT: Epidemiology of uveitis: incidence and prevalence in a small urban community. Arch Ophthalmol 1962, 68: 502–514. doi:10.1001/archopht.1962.00960030506014 10.1001/archopht.1962.00960030506014
Nussenblatt RB: The natural history of uveitis. Int Ophthalmol 1990,14(5–6):303–308. doi:10.1007/BF00163549
Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI: Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 2004, 88: 1159–1162. doi:10.1136/bjo.2003.037226 10.1136/bjo.2003.037226
Durrani OM, Meads CA, Murray PI: Uveitis: a potentially blinding disease. Ophthalmologica 2004, 218: 223–236. doi:10.1159/000078612 10.1159/000078612
Nguyen QD, Callanazn D, Dugel P, Godfrey DG, Goldstein DA, Wilensky JT: Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion. Retina 2006,26(suppl):1–16.
Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, Whitcup SM, Yocum D: Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000,130(4):492–513. 10.1016/S0002-9394(00)00659-0
Stanbury RM, Graham EM: Systemic corticosteroid therapy–side effects and their management. Br J Ophthalmol 1998,82(6):704–708. 10.1136/bjo.82.6.704
Nguyen QD, Hatef E, Kayen B, Macahilig CP, Ibrahim M, Wang J, Shaikh O, Bodaghi B: A cross-sectional study of the current treatment patterns in noninfectious uveitis among specialists in the United States. Ophthalmology 2011,118(1):184–190. doi:10.1016/j.ophtha.2010.03.029 10.1016/j.ophtha.2010.03.029
Imrie FR, Dick AD: Nonsteroidal drugs for the treatment of noninfectious posterior and intermediate uveitis. Curr Opin Ophthalmol 2007, 18: 212–219. 10.1097/ICU.0b013e3281107fef
Imrie FR, Dick AD: Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007, 18: 481–486. 10.1097/ICU.0b013e3282f03d42
Gritz DC, Wong IG: Incidence and prevalence of uveitis in Northern California. The Northern California Epidemiology of Uveitis Study. Ophthalmology 2004, 111: 491–500. 10.1016/j.ophtha.2003.06.014
Reeves SW, Sloan FA, Lee PP, Jaffe GJ: Uveitis in the elderly: epidemiological data from the National Long-term Care Survey Medicare Cohort. Ophthalmology 2006, 113: 302–307. 10.1016/j.ophtha.2005.10.008
Schneeweiss S, Avorn JA: Review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epi 2005, 58: 323–337. 10.1016/j.jclinepi.2004.10.012
Rein DB, Zhang P, Wirth KE, Lee PP, Hoerger TJ, McCall N, Klein R, Tielsch JM, Vijan S, Saaddine J: The economic burden of major adult visual disorders in the United States. Arch Ophthalmol 2006, 124: 1754–1760. 10.1001/archopht.124.12.1754
Hodge WG: Incidence and prevalence of uveitis in Northern California: discussion by. Ophthalmology 2004, 111: 500. doi:10.1016/j.ophtha.2003.10.017 10.1016/j.ophtha.2003.10.017
Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992,45(6):613–619. 10.1016/0895-4356(92)90133-8
Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M: A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007,10(1):3–12. 10.1111/j.1524-4733.2006.00139.x
McCannel CA, Holland GN, Helm CJ, Cornell PJ, Winston JV, Rimmer TG: Causes of uveitis in the general practice of ophthalmology: UCLA Community-Based Uveitis Study Group. Am J Ophthalmol 1996, 121: 35–46.
Bundorf MK, Royalty A, Baker LC: Health care cost growth among the privately insured. Health Aff (Millwood) 2009,28(5):1294–1304. Costs inflation adjusted to 2009 dollars using the medical Consumer Price Index. doi:10.1377/hlthaff.28.5.1294 10.1377/hlthaff.28.5.1294
Laliberté F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Piech CT, Lefebvre P: Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. J Manag Care Pharm 2009,15(4):312–322. Costs inflation adjusted to 2009 dollars using the medical Consumer Price Index
Chang S, Long SR, Kutikova L, Bowman L, Finley D, Crown WH, Bennett CL: Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol 2004,22(17):3524–3530. doi:10.1200/JCO.2004.10.170, Costs inflation adjusted to 2009 dollars using the medical Consumer Price Index 10.1200/JCO.2004.10.170
Standardization of Uveitis Nomenclature (SUN) Working Group: Standardization of uveitis nomenclature for reporting clinical data: results of the first international workshop. Am J Ophthalmol 2005, 140: 509–516. doi:10.1016/j.ajo.2005.03.057
Epstein AM, Cumella EJ: Capitation payment: using predictors for medical utilization to adjust rates. Health Care Financ Rev 1988, 10: 51–69.
Whittle J, Steinberg EP, Anderson GF, Herbert R: Accuracy of Medicare claims data for estimation of cancer incidence and resection rates among elderly Americans. Med Care 1991, 29: 1226–1236. 10.1097/00005650-199112000-00005